BYL-719 Alpelisib

Size	Price	Stock	Quantity
Get Quotation Now Add to Cart Bulk Inquiry

Shipping and handling fee USD40, Free delivery is qualified when the total value of your order exceeds USD500.If the item is temporarily out of stock. Please email to order@pharm-intermediates.com,we will inform you when we have it in stock.

Chemical Information

Product name：BYL-719 Alpelisib	Purity：98% min
CAS NO：1217486-61-7	Solubility：DMSO : ≥ 100 mg/mL (226.52 mM)
Molecular Formula：C₁₉H₂₂F₃N₅O₂S	Package：Package according to customer requirements
Molecular Weight：441.470	Storage：Store at -20℃

Quality control

COA

Remarks

Alpelisib, also known as BLY719, is an orally bioavailable phosphatidylinositol 3-kinase (PI3K) inhibitor with potential antineoplastic activity. PI3K inhibitor BYL719 specifically inhibits PIK3 in the PI3K/AKT kinase (or protein kinase B) signaling pathway, thereby inhibiting the activation of the PI3K signaling pathway. This may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis. Dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents. Check for active clinical trials or closed clinical trials using this agent.

Related Products:

Gedatolisib; AS-604850; CAY10505; AS-605240; Apitolisib; PIK-93; PIK-75 Hydrochloride; YM201636; ZSTK474; PI-103; PD98059; GNE-493; MTX-211; AKTIV; Duvelisib; TGX-221; LY294002

References

[1]. Furet P, et al. Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation. Bioorg Med Chem Lett. 2013 Jul 1;23(13):3741-8.

[2]. Fritsch C, et al. Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials. Mol Cancer Ther. 2014 May;13(5):1117-29.